https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Determinants of overall satisfaction with public clinics in rural China: interpersonal care quality and treatment outcome https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45166 p < 0.001), followed by two interpersonal care quality aspects, Dignity (being treated respectfully) (β = 0.219 (95% CI: 0.117 to 0.320); p < 0.001) and Communication (clear explanation by the physician) (β = 0.103 (95% CI: 0.003 to 0.203); p = 0.043). Prompt attention (waiting time before seeing the doctor) and Confidentiality (talking privately to the provider) were not correlated with overall satisfaction. The treatment outcome focus, and weak interpersonal primary care aspects, in overall patient satisfaction, pose barriers towards a patient-centered transformation of China’s primary care rural clinics, but support the focus of improving the clinical competency of rural primary care workers]]> Wed 26 Oct 2022 14:11:20 AEDT ]]> Current and evolving methods to visualize biological data in cancer research https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29578 Wed 17 Nov 2021 16:29:30 AEDT ]]> A Global Core Outcome Measurement Set for Snakebite Clinical Trials https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50616 Wed 15 May 2024 14:22:36 AEST ]]> Geographic remoteness from a multidisciplinary team is associated with an increased clinical staging of head and neck cancer: a Newcastle (Australia) study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47391 Wed 13 Mar 2024 08:10:34 AEDT ]]> The effect of curing hepatitis C with direct-acting antiviral treatment on endothelial function https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41650 Wed 10 Aug 2022 09:04:19 AEST ]]> Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35895 Tue 19 Jan 2021 18:44:28 AEDT ]]> Comparative effectiveness in multiple sclerosis: A methodological comparison https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51306 Thu 31 Aug 2023 14:27:51 AEST ]]> High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29998 –2) to determine melphalan AUC for a total of 114 patients. Binary logistic regression was used to assess whether melphalan AUC was associated with severe (≥ grade 3) oral mucositis. Multivariate Cox regression was used to assess whether melphalan AUC was significantly associated with time to progression, progression-free survival and overall survival (OS). Results: Melphalan AUC ranged from 4.9 to 24.6 mg l–1 h, median 12.84 mg l–1 h. Melphalan AUC above the median was a risk factor for severe mucositis (HR 1.21, 95% CI 1.06, 1.38, P = 0.004) but was also associated with significantly improved overall survival (OS) (HR 0.40, 95% CI 0.20, 0.81, P = 0.001), with an estimated median survival of 8.50 years vs. 5.38 years for high vs. low AUC groups. Multivariate analysis did not identify melphalan AUC as being significantly associated with time to progression or progression-free survival. Conclusions: This large scale pharmacodynamic analysis of HDM demonstrates that high melphalan exposure is associated with improved survival, with an acceptable increase in transplant toxicity. These results suggest studies targeting a higher AUC are warranted in patients undergoing HDM and ASCT for myeloma.]]> Thu 13 Jan 2022 10:31:39 AEDT ]]> Validation and implementation of the Australian Treatment Outcomes Profile in specialist drug and alcohol settings https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18578 Sat 24 Mar 2018 07:50:18 AEDT ]]> The impact of treatment on 3 years' outcome for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS) https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:5484 Sat 24 Mar 2018 07:47:05 AEDT ]]> A structured review of spinal stiffness as a kinesiological outcome of manipulation: its measurement and utility in diagnosis, prognosis and treatment decision-making https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25054 Sat 24 Mar 2018 07:10:43 AEDT ]]> Guidelines for composing and assessing a paper on treatment of pain https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34265 Mon 25 Feb 2019 11:39:14 AEDT ]]> Improved Quality of Life Following Addiction Treatment Is Associated with Reductions in Substance Use https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41496 Mon 08 Aug 2022 10:55:52 AEST ]]> Systematic Review and Meta-Analysis of a New Active Transcutaneous Bone Conduction Implant https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55067 Mon 08 Apr 2024 13:20:52 AEST ]]> Inhaled pirfenidone solution (AP01) for IPF: A randomised, open-label, dose-response trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51684 Fri 15 Sep 2023 09:37:14 AEST ]]> Patent ductus arteriosus management and the drift towards therapeutic nihilism – What is the evidence? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49392 Fri 12 May 2023 14:34:59 AEST ]]>